Table 4 |
|||||||
|
Clinical failures (CF) by day 42, 63 and 90 post-treatment, by clinical outcome at day 28 and treatment group |
|||||||
|
Outcome at D28° |
Treatment group (N) |
CF |
Total CF D29-90 |
||||
|
|
|||||||
|
D7-28 |
D29-42 |
D43-63 |
D64-90 |
||||
|
|
|||||||
|
ACPR (n = 123) |
SP-AS |
R |
0 |
0 |
0 |
0 |
0 |
|
|
|||||||
|
68 |
N |
0 |
0 |
2 |
5 |
7 |
|
|
|
|||||||
|
CQ |
R |
0 |
1 |
0 |
0 |
1 |
|
|
|
|||||||
|
18 |
N |
0 |
1 |
0 |
0 |
1 |
|
|
|
|||||||
|
SP37 |
R |
0 |
1 |
0 |
2 |
3 |
|
|
|
|||||||
|
37 |
N |
0 |
0 |
0 |
1 |
1 |
|
|
|
|||||||
|
LPF new infection (n = 7) |
SP-AS |
R |
0 |
0 |
0 |
0 |
0 |
|
|
|||||||
|
4 |
N |
0 |
1 |
0 |
0 |
1 |
|
|
|
|||||||
|
CQ |
R |
0 |
0 |
0 |
0 |
0 |
|
|
|
|||||||
|
2 |
N |
0 |
0 |
0 |
0 |
0 |
|
|
|
|||||||
|
SP |
R |
0 |
0 |
0 |
0 |
0 |
|
|
|
|||||||
|
1 |
N |
0 |
0 |
0 |
1 |
1 |
|
|
|
|||||||
|
LPF recrudescence (n = 38) |
SP-AS |
R |
0 |
0 |
1 |
0 |
1 |
|
|
|||||||
|
3 |
N |
0 |
0 |
0 |
0 |
0 |
|
|
|
|||||||
|
CQ |
R |
3 |
0 |
0 |
0 |
3 |
|
|
|
|||||||
|
25 |
N |
0 |
0 |
1 |
2 |
3 |
|
|
|
|||||||
|
SP |
R |
4 |
0 |
0 |
0 |
4 |
|
|
|
|||||||
|
10 |
N |
0 |
0 |
0 |
0 |
0 |
|
|
|
|||||||
|
°ACPR: Adequate Clinical and Parasitological Response; LPF: Late Parasitological Failure; R = recrudescence; N = new infection; D = day). |
|||||||
|
Nahum et al. Malaria Journal 2009 8:37 doi:10.1186/1475-2875-8-37 |
|||||||
